Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), sold 20,994 shares at $75.21 ($1.6M) on 2024-05-28, disclosed to the SEC on 2024-05-29.
Scheduled sale ($1.6M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.21 | 5,249 | $395K | 25.0% |
| 2 | $75.21 | 5,249 | $395K | 25.0% |
| 3 | $75.14 | 5,248 | $394K | 25.0% |
| 4 | $75.14 | 5,248 | $394K | 25.0% |
| Total | $75.18 avg | 20,994 | $1.6M | 100% |
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |